Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

By T. Walsh, H. Teppler, G. Donowitz, J. Maertens, L. Baden, A. Dmoszyńska, O. Cornely, M. Bourque, R. Lupinacci, C. Sable and 1 more. New England Journal of Medicine, 2004

876 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/59c56da9a9610d2a11b7ca9bed031dab07665404

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Perfect
2. M. Arendrup
3. D. Kontoyiannis
4. T. Walsh
5. Thierry Calandra
6. E. Anaissie
7. M. Pfaller
8. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. J. Perfect
3. M. Arendrup
4. Henry F. Chambers
5. J. Bartlett
6. E. Anaissie
7. M. Pfaller
8. D. Diekema

Citations in the corpus

• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, result): “This trial found that caspofungin was as effective as L-AMB in overall response; prespecified secondary analyses found that caspofungin was more active in prolongation of survival and in primary treatment of baseline invasive fungal infections [263].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Among the echinocandins, caspofungin has been shown to be as effective as and better tolerated than L-AmB for empirical therapy [91].”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “This recommendation is based on limited data from prospective randomized trials and has been associated with few complications and relapses [209,210].”
• Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018, background): “Empiric antifungal treatment is expected to reduce morbidity [181e186] and mortality [187,188] (Table 29).”
• Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, background): “efficacy, in strategy trials [2–6], for the formulation of clinical”
• Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. (2006, background): “Studies examining the efficacy of caspofungin, liposomal amphotericin B, and voriconazole (an azole) have shown very low success rates of ∼40% [41–43].”
• Practice guidelines for the diagnosis and management of skin and soft-tissue infections. (2005, background): “Recently, 2 randomized, international, multicenter trials found that caspofungin [181] and voriconazole [182] were each suitable alternatives to amphotericin B in this patient population.”
• Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (2007, background): “More than 1300 patients received liposomal amphotericin B at 3 mg/kg per day in 3 major clinical trials of empirical antifungal therapy for febrile neutropenia [7, 22, 23].”